article thumbnail

ORBITA-2: Objective Randomized Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina

American College of Cardiology

The ORBITA-2 (Objective Randomized Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina) trial data demonstrate that, in patients with stable angina and ischemia producing coronary stenoses.

Angina 51
article thumbnail

Objective Randomized Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina

American College of Cardiology

The goal of the ORBITA-2 trial was to assess the efficacy of percutaneous coronary intervention (PCI) compared with a sham placebo procedure for angina relief among patients with stable angina who were not on background antianginal medication.

Angina 58
article thumbnail

Responders to PCI for Angina Relief Identified by Chest Pain Type

Med Page Today

(MedPage Today) -- PARIS -- Whether a person had chest pains resolved by angioplasty hinged on the nature, not the severity, of their presenting symptoms, an ORBITA-2 analysis showed. Investigators found two groups more likely to benefit from.

article thumbnail

Percutaneous revascularisation in chronic coronary syndromes: when real-world data unveil the other side of the coin

Heart BMJ

1 Indeed, if the recently published ORBITA-2 trial demonstrated the benefit of revascularisation in relieving angina symptoms, 2 many other trials aiming to show a benefit on hard outcomes have failed in their purpose. 3 The ISCHEMIA-EXTEND reported the extended follow-up of the recent ISCHEMIA trial.

article thumbnail

BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

DAIC

Results from the open label roll-in cohort of patients having chronic myocardial ischemia with refractory angina showed an average increase in exercise tolerance of 107 seconds and an average of 82% reduction in angina episodes at the primary six-month follow-up endpoint compared to before receiving the study treatment.

article thumbnail

25th Anniversary of a landmark study in coronary revascularization

Dr. S. Venkatesan MD

One clue : We do prescribe this drug every day and it beats angioplasty. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. This conclusion is explicitly illustrated here, and the dramatically dissociated Kaplan and Myers would tell the whole story. Some of you may have got it right.

article thumbnail

Abstract 4140682: Clinical Case: Flipping the Script: Tackling CAD in Dextrocardia During Cardiac Catheterization

Circulation

Patients with dextrocardia present a diagnostic challenge, particularly in the context of acute coronary syndrome.Case Presentation:A 49-year-old male with a medical history of dextrocardia, hypothyroidism, dyslipidemia and hypertension was referred to a cardiologist by his primary physician due to a 3-week history of unstable angina.